GlassScriptPhysician profile
Sarah Trimble
NPI 1083925770
$1,437.04
in general payments reported to CMS, 2019-2025
17 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $193 · 2023: $425 · 2024: $259 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.71 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $293.01 | 2022-2025 | Annovera, Nextstellis |
| Abbvie INC. | $248.11 | 2021-2024 | |
| Astellas Pharma US INC | $240.12 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $143.12 | 2021-2022 | |
| Exeltis, USA INC. | $95.94 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $72.44 | 2023 | Myfembree, Gemtesa |
| Shield Therapeutics INC | $54.16 | 2024-2025 | |
| Hologic Sales and Service, LLC | $52.15 | 2022-2025 | Fetal Fibronectin Enzyme Immunoassay, Aptima |
| Pfizer INC. | $43.73 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.69 | 2022-2025 | |
| Organon LLC | $28.67 | 2022-2023 | Nexplanon |
| Myovant Sciences INC. | $26.30 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.96 | 2023 | Seglentis |
| Coopersurgical, INC. | $20.64 | 2024 | Paragard T 380a |
| Evofem Biosciences, INC. | $20.01 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.74 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Millicent US INC | $16.25 | 2025 | Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Trimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.